MarketBeat
21 Nov 2026, 05:12 UTC · 1h ago
Recursion Pharmaceuticals Reaches FDA Agreement on Key Endpoint for Phase III FAP Trial
Impact · against what's priced in
RXRX gains a positive catalyst through FDA alignment on Phase III endpoints for FAP, though the timeline pushes the first potential readout to 2028. Reduced cash burn and oncology pipeline milestones for H2 2027 provide medium-term valuation support.
- RXRX+0.60
No priced-in read yet





